SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 3×
“The fact that similar findings were seen in the subset of those who were sequenced, also supports our conclusions (Tegally et al., 2021).”
InfluentialSelf-citationSARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · cited 2×
“Neutralizing antibodies are widely assumed to be a correlate of protection from SARS-CoV-2 infection (Folegatti et al., 2020, Jackson et al., 2020, Rogers et al., 2020).”
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651 · cited 4×
“These confer partial to complete resistance to convalescent plasma and to some monoclonal antibodies (mAbs), including class I/II RBD-directed mAbs and 4A8 which targets the NTD (Wibmer et al., 2021, Cele et al., 2021, Wang et al., 2021a).”
InfluentialSelf-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651
Self-citationNeutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., et al. (2021) · Science · doi:10.1126/science.abg6105 · Cited by 515 · cited 1×
“The 501Y.V1 variant did not show substantially increased resistance to neutralizing antibodies, though the subsequent emergence within this lineage of the E484K mutation suggests immune escape (Muik et al., 2021, Wu et al., 2021, Li et al., 2021, Graham et al., 2021, Wise, 2021).”
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364 · cited 1×
“Although 501Y.V2 is resistant to class I/II RBD-directed antibodies, class III and IV RBD-specific antibodies are not affected by the RBD changes in the 501Y.V2 variant (Yuan et al., 2021, Wang et al., 2021a).”
Research works printed but not linked: 29
- 2020, Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes, Bioinformatics, 36, 3552, 10.1093/bioinformatics/btaa145 · DOI · Paper page
- 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, The Lancet, 396, 467, 10.1016/S0140-6736(20)31604-4 · DOI · Paper page
- Fontanet, A. , Autran, B. , Lina, B. , Kieny, M. P. , Karim, S. S. A. & Sridhar, D. 2021. SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet. · DOI · Paper page
- Garcia-Beltran, W. F. , Lam, E. C. , Denis, K. S. , Nitido, A. D. , Garcia, Z. H. , Hauser, B. M. , Feldman, J. , Pavlovic, M. N. , Gregory, D. J. & Poznansky, M. C. 2021. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. · DOI · Paper page
- Gavor, E. , Choong, Y. K. , Er, S. Y. , Sivaraman, H. & Sivaraman, J. 2020. Structural basis of SARS-CoV-2 and SARS-CoV–antibody interactions. Trends in Immunology. · DOI
- Huang, Y. , Nguyen, A. W. , Hsieh, C.-L. , Silva, R. , Olaluwoye, O. S. , Wilen, R. , Kaoud, T. S. , Azouz, L. R. , Qerqez, A. N. & Le, K. C. 2021. Identification of a conserved neutralizing epitope present on spike proteins from highly pathogenic coronaviruses. bioRxiv. · DOI
- 10.1093/molbev/mst010 · DOI · Paper page
- Korber, B. , Fischer, W. , Gnanakaran, S. , Yoon, H. , Theiler, J. , Abfalterer, W. , Foley, B. , Giorgi, E. , Bhattacharya, T. , Parker, M. , Partridge, D. , Evans, C. , De Silva, T. , Labranche, C. & Montefiori, D. 2020a. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv, 2020.04.29.069054.
- 10.1016/j.cell.2020.06.043 · DOI · Paper page
- 2020, Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity, Immunity, 53, 1272, 10.1016/j.immuni.2020.10.023 · DOI · Paper page
- Liu, H. , Zhang, Q. , Wei, P. , Chen, Z. , Aviszus, K. , Yang, J. , Downing, W. , Peterson, S. , Jiang, C. , Liang, B. , Reynoso, L. , Downey, G. P. , Frankel, S. K. , Kappler, J. , Marrack, P. & Zhang, G. 2021. The basis of a more contagious 501Y.V1 variant of SARS-COV-2. bioRxiv, 2021.02.02.428884.
- Madhi, S. A. , Baillie, V. L. , Cutland, C. L. , Voysey, M. , Koen, A. L. , Fairlie, L. , Padayachee, S. D. , Dheda, K. , Barnabas, S. L. & Bhorat, Q. E. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa. medRxiv. · DOI · Paper page
- 2020, Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques, Nature, 586, 583, 10.1038/s41586-020-2607-z · DOI · Paper page
- 10.1093/molbev/msu300 · DOI · Paper page
- 2020, Whole genome sequencing of SARS-CoV-2: adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic, Genes, 11, 949, 10.3390/genes11080949 · DOI
- Rappazzo, C. G. , Longping, V. T. , Kaku, C. I. , Wrapp, D. , Sakharkar, M. , Huang, D. , Deveau, L. M. , Yockachonis, T. J. , Herbert, A. S. & Battles, M. B. 2021. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. · DOI · Paper page
- Rawat, K. , Kumari, P. & Saha, L. 2020. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology, 173751.
- Stamatatos, L. , Czartoski, J. , Wan, Y.-H. , Homad, L. J. , Rubin, V. , Glantz, H. , Neradilek, M. , Seydoux, E. , Jennewein, M. F. , Maccamy, A. J. , Feng, J. , Mize, G. , De Rosa, S. C. , Finzi, A. , Lemos, M. , Cohen, K. W. , Moodie, Z. , Mcelrath, M. J. & Mcguire, A. T. 2021. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. medRxiv, 2021.02.05.21251182.
- Wang, L. , Zhou, T. , Zhang, Y. , Yang, E. S. , Schramm, C. A. , Shi, W. , Pegu, A. , Oloninyi, O. K. , Ransier, A. , Darko, S. , Narpala, S. R. , Hatcher, C. , Martinez, D. R. , Tsybovsky, Y. , Phung, E. , Abiona, O. M. , Cale, E. M. , Chang, L. A. , Corbett, K. S. , Dipiazza, A. T. , Gordon, I. J. , Leung, K. , Liu, T. , Mason, R. D. , Nazzari, A. , Novik, L. , Olia, A. S. , Doria-Rose, N. A. , Stephens, T. , Stringham, C. D. , Talana, C. A. , Teng, I.-T. , Wagner, D. , Widge, A. T. , Zhang, B. , Roederer, M. , Ledgerwood, J. E. , Ruckwardt, T. J. , Gaudinski, M. R. , Baric, R. S. , Graham, B. S. , Mcdermott, A. B. , Douek, D. C. , Kwong, P. D. , Mascola, J. R. , Sullivan, N. J. & Misasi, J. 2021a. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv, 2021.02.25.432969.
- Wang, P. , Nair, M. S. , Liu, L. , Iketani, S. , Luo, Y. , Guo, Y. , Wang, M. , Yu, J. , Zhang, B. , Kwong, P. D. , Graham, B. S. , Mascola, J. R. , Chang, J. Y. , Yin, M. T. , Sobieszczyk, M. , Kyratsous, C. A. , Shapiro, L. , Sheng, Z. , Huang, Y. & Ho, D. D. 2021b. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv, 2021.01.25.428137.
- Wang, P. , Wang, M. , Yu, J. , Cerutti, G. , Nair, M. S. , Huang, Y. , Kwong, P. D. , Shapiro, L. & HO, D. D. 2021 c. Increased Resistance Of SARS-CoV-2 Variant P.1 to Antibody Neutralization . bioRxiv, 2021.03.01.433466.
- Wibmer, C. K. , Ayres, F. , Hermanus, T. , Madzivhandila, M. , Kgagudi, P. , Oosthuysen, B. , Lambson, B. E. , De Oliveira, T. , Vermeulen, M. , Van Der Berg, K. , Rossouw, T. , Boswell, M. , Ueckermann, V. , Meiring, S. , Von Gottberg, A. , Cohen, C. , Morris, L. , Bhiman, J. N. & Moore, P. L. 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine. · DOI · Paper page
- Wickham, H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag: New York, NY, USA. · DOI · Paper page
- Wise, J. 2021. Covid-19: The E484K mutation and the risks it poses. British Medical Journal Publishing Group. · DOI · Paper page
- Wu, K. , Werner, A. P. , Moliva, J. I. , Koch, M. , Choi, A. , Stewart-Jones, G. B. E. , Bennett, H. , Boyoglu-Barnum, S. , Shi, W. , Graham, B. S. , Carfi, A. , Corbett, K. S. , Seder, R. A. & Edwards, D. K. 2021. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv, 2021.01.25.427948.
- 10.1126/science.abc6284 · DOI · Paper page
- Zhang, L. , Jackson, C. B. , Mou, H. , Ojha, A. , Rangarajan, E. S. , Izard, T. , Farzan, M. & Choe, H. 2020a. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv, 2020.06.12.148726.
- Zhang, Y.-J. , Zeng, G. , Pan, H.-X. , Li, C.-G. , Kan, B. , Hu, Y.-L. , Mao, H.-Y. , Xin, Q.-Q. , Chu, K. & Han, W.-X. 2020b. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medrxiv. · DOI
- 10.1038/s41586-020-2012-7 · DOI · Paper page
Cited by
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 351
Mandolo, J., Msefula, J., Henrion, M. Y. R., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02187-y · Cited by 61
“previous studies showing that homologous convalescent sera retain higher in vitro neutralisation potency than heterologous convalescent sera against the infecting virus [16, 21, 24, 25].”
Self-citationFaulkner, N., Ng, K. W., Wu, M. Y., Harvey, R., Margaritis, M., Paraskevopoulou, S., Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021) · eLife · doi:10.7554/elife.69317 · Cited by 52
Barreiro, A., Prenafeta, A., Bech-Sabat, G., Roca, M., Perozo Mur, E., March, R., González-González, L., Madrenas, L., Corominas, J., Fernández, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106126 · Cited by 28
“4,5 Moreover, it is of relevance that these recent vaccines can be stored in refrigerated conditions, making them easier to distribute and avoiding more expensive and less available ultra-low temperature storage and transport conditions to ensure their global supply.”
Metadata
- Authors
- Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., Rossouw, T., Boswell, M., de Oliveira, T., Williamson, C., Burgers, W. A., Ntusi, N., Morris, L., & Moore, P. L.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2021-03-06
- OpenAlex
- W3135007751
- Cited by
- 36
- References
- 13
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. https://app.cochat.ai/papers/10.1101/2021.03.06.434193
- The paper
- Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., . . . Moore, P. L. (2021). SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.03.06.434193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.